MeSH term
Frequency | Condition_Probility | Acute Disease | 2 | 0.0 |
Adult | 12 | 0.0 |
Comparative Study | 7 | 0.0 |
Humans | 118 | 0.0 |
Animals | 36 | 0.0 |
Oligonucleotide Array Sequence Analysis | 2 | 0.0 |
Immunohistochemistry | 12 | 0.0 |
*Intercellular Signaling Peptides and Proteins | 2 | 0.0 |
Lymph Nodes/pathology | 2 | 0.0 |
Research Support, Non-U.S. Gov't | 80 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 15 | 0.0 |
Tumor Cells, Cultured | 16 | 0.0 |
MAP Kinase Kinase 1 | 2 | 1.0 |
MAP Kinase Signaling System/drug effects | 2 | 2.0 |
Mitogen-Activated Protein Kinase Kinases/antagonists & inhibitors | 2 | 4.0 |
Protein-Serine-Threonine Kinases/antagonists & inhibitors | 2 | 2.0 |
Research Support, U.S. Gov't, P.H.S. | 37 | 0.0 |
Signal Transduction/*drug effects | 2 | 0.0 |
Cell Line, Tumor | 11 | 0.0 |
Cell Movement/drug effects | 4 | 1.0 |
Dose-Response Relationship, Drug | 7 | 0.0 |
*Gene Expression Profiling | 2 | 0.0 |
Gene Expression Regulation/*drug effects | 2 | 0.0 |
RANTES/*pharmacology | 2 | 11.0 |
RNA, Messenger/metabolism | 6 | 0.0 |
Receptors, CCR5/metabolism | 3 | 2.0 |
Receptors, CXCR4/metabolism | 11 | 7.0 |
Reverse Transcriptase Polymerase Chain Reaction/methods | 2 | 0.0 |
Time Factors | 7 | 0.0 |
Phosphorylation/drug effects | 3 | 0.0 |
Amino Acid Sequence | 6 | 0.0 |
Cell Line | 13 | 0.0 |
Molecular Sequence Data | 6 | 0.0 |
Mice | 23 | 0.0 |
Mice, Inbred C57BL | 4 | 0.0 |
Microscopy, Confocal | 2 | 0.0 |
Vascular Cell Adhesion Molecule-1/metabolism | 4 | 4.0 |
Apoptosis | 4 | 0.0 |
Calcium/metabolism | 11 | 0.0 |
Chemokines, CXC/*metabolism | 5 | 9.0 |
Flow Cytometry | 14 | 0.0 |
*Gene Expression Regulation, Neoplastic | 4 | 0.0 |
RNA, Messenger/genetics/metabolism | 4 | 0.0 |
Receptors, CXCR4/*metabolism | 6 | 3.0 |
*Signal Transduction | 5 | 0.0 |
Aged | 8 | 0.0 |
Aged, 80 and over | 5 | 0.0 |
*Chemotaxis | 4 | 12.0 |
Ligands | 11 | 0.0 |
Middle Aged | 10 | 0.0 |
Cytokines/*pharmacology | 2 | 0.0 |
Granulocyte Colony-Stimulating Factor/pharmacology | 2 | 1.0 |
RNA, Messenger/analysis | 6 | 0.0 |
Adenosine Diphosphate Ribose/metabolism | 2 | 3.0 |
Cells, Cultured/drug effects | 2 | 2.0 |
Chemotaxis/drug effects | 4 | 4.0 |
Enzyme-Linked Immunosorbent Assay | 8 | 0.0 |
RNA, Messenger/biosynthesis | 2 | 0.0 |
Rats | 9 | 0.0 |
Cytokines/*immunology | 2 | 2.0 |
Killer Cells, Natural/*immunology | 3 | 0.0 |
Blotting, Western | 5 | 0.0 |
*Cell Adhesion | 2 | 1.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 10 | 0.0 |
Blotting, Northern | 2 | 0.0 |
Cell Division | 5 | 0.0 |
Cell Membrane/metabolism | 3 | 0.0 |
Chemokines, CXC/*physiology | 7 | 17.0 |
Chemotaxis | 6 | 3.0 |
*Gene Expression Regulation | 2 | 0.0 |
Signal Transduction | 7 | 0.0 |
1-Phosphatidylinositol 3-Kinase/physiology | 5 | 4.0 |
Gene Expression | 2 | 0.0 |
Receptors, CXCR4/*physiology | 6 | 12.0 |
Cell Adhesion/immunology | 5 | 2.0 |
Cell Membrane/immunology/metabolism | 2 | 1.0 |
Chemotaxis, Leukocyte/*immunology | 3 | 6.0 |
Female | 27 | 0.0 |
Mice, Inbred BALB C | 5 | 0.0 |
Organ Specificity/immunology | 2 | 6.0 |
Receptors, CXCR4/biosynthesis | 4 | 12.0 |
Receptors, Chemokine/biosynthesis | 3 | 6.0 |
Endothelium, Lymphatic/metabolism/pathology | 2 | 66.0 |
Arthritis, Rheumatoid/*immunology | 3 | 1.0 |
Enzyme Activation | 4 | 0.0 |
Fibroblasts/metabolism | 2 | 0.0 |
Mitogen-Activated Protein Kinase 1/metabolism | 4 | 1.0 |
Mitogen-Activated Protein Kinase 3 | 5 | 0.0 |
Mitogen-Activated Protein Kinases/metabolism | 7 | 0.0 |
Chemokines, CXC/metabolism/physiology | 2 | 66.0 |
Jurkat Cells | 3 | 0.0 |
Signal Transduction/*immunology | 3 | 0.0 |
Male | 14 | 0.0 |
Cells, Cultured | 21 | 0.0 |
Receptors, Chemokine/immunology | 3 | 9.0 |
Cell Movement/*physiology | 5 | 2.0 |
RNA, Messenger/biosynthesis/genetics | 2 | 0.0 |
Receptors, CXCR4/genetics/metabolism/*physiology | 2 | 100.0 |
Stromal Cells/metabolism | 2 | 2.0 |
In Vitro | 8 | 0.0 |
Rats, Sprague-Dawley | 2 | 0.0 |
Receptors, Chemokine/*biosynthesis | 2 | 5.0 |
Catalysis | 2 | 0.0 |
Protein Binding | 5 | 0.0 |
Receptors, Chemokine/metabolism | 2 | 1.0 |
Adolescent | 4 | 0.0 |
Chemokines, CXC/metabolism | 6 | 7.0 |
Child | 4 | 0.0 |
Lymphocyte Activation/immunology | 2 | 0.0 |
Neoplasm Invasiveness | 4 | 0.0 |
Receptors, Chemokine/*metabolism | 4 | 2.0 |
Chemotaxis, Leukocyte/immunology | 4 | 6.0 |
Signal Transduction/immunology | 4 | 1.0 |
Cell Differentiation | 2 | 0.0 |
Cell Movement | 7 | 0.0 |
Chemokines, CXC/genetics/metabolism | 2 | 33.0 |
Disease Progression | 2 | 0.0 |
Gene Expression Profiling | 2 | 0.0 |
Antineoplastic Agents/pharmacology | 2 | 0.0 |
Phenotype | 4 | 0.0 |
Biopsy | 2 | 0.0 |
Intercellular Signaling Peptides and Proteins/genetics/metabolism | 2 | 9.0 |
Receptors, CXCR4/genetics/metabolism | 2 | 8.0 |
Cell Movement/*drug effects | 2 | 2.0 |
Protein-Tyrosine Kinase/metabolism | 8 | 0.0 |
Proto-Oncogene Proteins/metabolism | 3 | 0.0 |
Signal Transduction/drug effects | 3 | 0.0 |
Quinolinic Acid/*pharmacology | 2 | 40.0 |
Cell Adhesion/drug effects | 3 | 0.0 |
Hyperplasia | 2 | 0.0 |
Lymphatic Metastasis | 2 | 0.0 |
Mice, Inbred NOD | 3 | 1.0 |
Mice, SCID | 4 | 0.0 |
Cell Division/physiology | 2 | 0.0 |
Chemotaxis/physiology | 3 | 9.0 |
Mutation | 2 | 0.0 |
Receptors, Cytokine/metabolism | 2 | 2.0 |
Chemokines, CXC/physiology | 2 | 9.0 |
Receptors, CXCR4/*genetics | 2 | 7.0 |
T-Lymphocytes/*drug effects/metabolism | 2 | 5.0 |
Up-Regulation | 5 | 0.0 |
Models, Immunological | 2 | 0.0 |
Gene Expression Regulation/immunology | 2 | 1.0 |
Up-Regulation/immunology | 2 | 1.0 |
Base Sequence | 7 | 0.0 |
Neoplasm Staging | 2 | 0.0 |
Chemokines, CXC/pharmacology | 4 | 5.0 |
Lymphocyte Activation | 2 | 0.0 |
Phosphorylation | 15 | 0.0 |
Culture Media, Conditioned | 2 | 0.0 |
Down-Regulation/drug effects | 2 | 0.0 |
Endothelium, Vascular/cytology | 2 | 0.0 |
Fibronectins/metabolism | 2 | 1.0 |
*Neoplasm Metastasis | 2 | 2.0 |
Receptors, CXCR4/*biosynthesis | 3 | 9.0 |
Chemokines, CXC/*genetics | 3 | 9.0 |
Gene Expression/immunology | 3 | 3.0 |
Receptors, Antigen, T-Cell/metabolism | 2 | 1.0 |
Colony-Forming Units Assay | 2 | 0.0 |
Protease Inhibitors/pharmacology | 2 | 0.0 |
Recombinant Proteins/pharmacology | 3 | 0.0 |
Cell Movement/*immunology | 3 | 4.0 |
Cytosol/metabolism | 2 | 0.0 |
Cell Division/drug effects | 2 | 0.0 |
HIV-1/*physiology | 2 | 0.0 |
Cell Survival/drug effects | 2 | 0.0 |
Pregnancy | 2 | 0.0 |
B-Lymphocytes/metabolism/pathology | 2 | 15.0 |
Chemokines, CXC/metabolism/*physiology | 4 | 44.0 |
Chemokines, CXC/*pharmacology | 3 | 9.0 |
Cell Adhesion | 2 | 0.0 |
Mitogen-Activated Protein Kinases/physiology | 2 | 1.0 |
Tyrosine/metabolism | 3 | 0.0 |
Actins/metabolism | 3 | 0.0 |
Protein Kinase C/physiology | 3 | 1.0 |
Chemokines, CXC/genetics/physiology | 2 | 66.0 |
DNA Primers | 5 | 0.0 |
RNA, Messenger/genetics | 4 | 0.0 |
Receptors, CXCR4/genetics/*physiology | 3 | 33.0 |
Recombinant Proteins/metabolism | 2 | 0.0 |
Precipitin Tests | 2 | 0.0 |
*Protein-Serine-Threonine Kinases | 3 | 0.0 |
Chemokines, CXC/genetics/*metabolism | 3 | 18.0 |
Pertussis Toxin/pharmacology | 3 | 5.0 |
Stromal Cells/immunology/metabolism | 2 | 13.0 |
*Cell Migration Inhibition | 2 | 5.0 |
Protein-Tyrosine Kinase/physiology | 2 | 1.0 |
Anti-HIV Agents/*pharmacology | 2 | 1.0 |
Chemotaxis, Leukocyte/drug effects | 2 | 2.0 |
Neoplasm Metastasis | 2 | 0.0 |
Receptors, CXCR4/*antagonists & inhibitors | 2 | 7.0 |
CHO Cells | 3 | 0.0 |
Hamsters | 4 | 0.0 |
Cell Cycle | 2 | 0.0 |
Transfection | 3 | 0.0 |
T-Lymphocytes/immunology | 2 | 0.0 |
Receptors, Chemokine/genetics/metabolism | 2 | 8.0 |
Coculture Techniques | 2 | 0.0 |
Receptors, CXCR4/genetics/*metabolism | 2 | 4.0 |
Receptors, CXCR4/*immunology | 3 | 18.0 |
MAP Kinase Signaling System | 2 | 0.0 |
Cell Survival | 2 | 0.0 |
Microscopy, Fluorescence | 2 | 0.0 |
Chickens | 2 | 0.0 |
CD40 Ligand/pharmacology | 2 | 7.0 |
Interleukin-4/pharmacology | 2 | 0.0 |
Interleukin-1/pharmacology | 2 | 0.0 |
Tumor Necrosis Factor-alpha/pharmacology | 2 | 0.0 |
